Oncosil Medical Ltd
ASX:OSL
Intrinsic Value
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. [ Read More ]
The intrinsic value of one
OSL
stock under the Base Case scenario is
0.173
AUD.
Compared to the current market price of 0.007 AUD,
Oncosil Medical Ltd
is
Undervalued by 96%.
Oncosil Medical Ltd's market capitalization is 14.6m AUD.
OSL stock price is 0.007 AUD.
OSL stock price (0.007 AUD) is 96% less than its Intrinsic Value (0.173 AUD).
OSL stock (0.002 AUD) is 77% less than its price (0.007 AUD). Open Relative Valuation
OSL.
OSL's Revenue has dropped by 49% over the past 12 months.
OSL's ROE (Return on Equity) has significantly decreased in the last 3 years from -46% to -238%, and is approaching profitability.
OSL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 387% to -5 434%, and is approaching profitability.
OSL has negative Operating Income for the last twelve months.
OSL has negative Net Income for the last twelve months.
OSL's ROE (Return on Equity) for the past 12 months is negative and is equal to -238%.
OSL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -5 434%.
OSL has negative Gross Profit for the last twelve months.
OSL's long-term assets (6m AUD) exceed its long-term liabilties (2m AUD).
OSL's short-term assets (6m AUD) exceed its short-term liabilties (2m AUD).
OSL has negative Free Cash Flow for the last twelve months.
OSL's Revenue has been falling by 47% per year for the last 3 years.
OSL's D/E (Debt to Equity) is very low and is equal to 0.02.
OSL has negative three-year average ROE (Return on Equity): -118%. The company is not efficient at transforming stockholders' equity into net income.
OSL has negative three-year average ROIC (Return on Invested Capital): -2 844%. The company is not efficient at using invested capital to generate operating income.
OSL has negative Net Debt. This means that the company has more cash and short-term investments (5m AUD) than debt (73k AUD).
OSL's Altman Z-Score is very low and is equal to -19.16.
OSL earns more than enough operating income (-12m AUD) to safely cover interest payments on its debt (-9k AUD).
Fundamental Analysis
Oncosil Medical Ltd
Balance Sheet Decomposition
Oncosil Medical Ltd
| Current Assets | 6.3m |
| Cash & Short-Term Investments | 4.9m |
| Receivables | 692.6k |
| Other Current Assets | 666.6k |
| Non-Current Assets | 186k |
| PP&E | 186k |
| Other Non-Current Assets | -10 |
| Current Liabilities | 2.3m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 241.5k |
| Other Current Liabilities | 145k |
| Non-Current Liabilities | 72.8k |
| Long-Term Debt | 72.8k |
Earnings Waterfall
Oncosil Medical Ltd
|
Revenue
|
355.3k
AUD
|
|
Cost of Revenue
|
-1.9m
AUD
|
|
Gross Profit
|
-1.5m
AUD
|
|
Operating Expenses
|
-10m
AUD
|
|
Operating Income
|
-11.5m
AUD
|
|
Other Expenses
|
-167.4k
AUD
|
|
Net Income
|
-11.7m
AUD
|
Free Cash Flow Analysis
Oncosil Medical Ltd
What is Free Cash Flow?
OSL Profitability Score
Profitability Due Diligence
Oncosil Medical Ltd's profitability score is 4/100. The higher the profitability score, the more profitable the company is.
Score
Oncosil Medical Ltd's profitability score is 4/100. The higher the profitability score, the more profitable the company is.
OSL Solvency Score
Solvency Due Diligence
Oncosil Medical Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Oncosil Medical Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OSL Price Targets Summary
Oncosil Medical Ltd
Shareholder Return
OSL Price
Oncosil Medical Ltd
| Average Annual Return | 28.56% |
| Standard Deviation of Annual Returns | 118.02% |
| Max Drawdown | -98% |
| Market Capitalization | 14.6m AUD |
| Shares Outstanding | 2 255 539 968 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Oncosil Medical Ltd
Country
Industry
Market Cap
Dividend Yield
Description
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
You don't have any saved screeners yet
